Noxafil and Pepcid AC
Determining the interaction of Noxafil and Pepcid AC and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:The following interaction applies only if you are receiving the oral suspension of posaconazole (Noxafil), but not the other formulations: Talk to your doctor before using posaconazole together with famotidine. By reducing stomach acid, famotidine can decrease the absorption and blood levels of posaconazole and make the medication less effective against fungal infections. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. A temporary discontinuation of famotidine may also be considered until you have completed treatment with posaconazole. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration with H2-receptor antagonists may decrease the systemic bioavailability of posaconazole from the oral suspension. The proposed mechanism is reduced solubility and absorption of posaconazole due to an increase in gastric pH induced by these agents. In healthy volunteers, posaconazole mean peak plasma concentration (Cmax) and systemic exposure (AUC) were each reduced by 39% during coadministration of posaconazole 200 mg once a day with cimetidine 400 mg twice a day for 10 days. Based on this and other data reported in the literature, particularly with proton pump inhibitors, it appears likely that posaconazole oral bioavailability from non-delayed release formulations is at least partially dependent on gastric pH. However, the product labeling states that no clinically relevant effects on posaconazole bioavailability, efficacy, or safety were observed when the oral suspension is administered with an H2 antagonist other than cimetidine, and no particular precaution is recommended during concomitant use except with cimetidine. Several published studies investigating the factors affecting posaconazole plasma concentrations in various patient cohorts found no association with ranitidine exposure, and a pharmacokinetic subanalysis conducted in a pivotal phase 3 clinical trial also reported no effect of H2 antagonists on posaconazole concentration, while a study from Australia identified ranitidine use as a significant factor in reduced posaconazole concentrations in a multiple linear regression analysis. The reason for this discrepancy has not been established.
MANAGEMENT: Concomitant use of posaconazole oral suspension with cimetidine should generally be avoided. Until more information is available, this precaution should also be considered for other H2-receptor antagonists, although the manufacturer suggests otherwise. If possible, prescribers may consider suspending the H2 antagonist until completion of posaconazole therapy, or substituting an antifungal agent like fluconazole or voriconazole whose absorption is not affected by stomach pH. Delayed-release tablets of posaconazole may be used with H2 antagonists, as no pharmacokinetic interaction has been demonstrated with ranitidine or other agents affecting gastric pH such as proton pump inhibitors or antacids.
- Krishna G, Moton A, Ma L, Medlock MM, McLeod J "The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers." Antimicrob Agents Chemother 53 (2009): 958-66
- Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR "Omeprazole significantly reduces posaconazole serum trough level." Clin Infect Dis 48 (2009): 839
- Shields RK, Clancy CJ, Vadnerkar A, et al "Posaconzaole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy." Antimicrob Agents Chemother 55 (2011): 1308-11
- Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
- Krishna G, Moton A, Ma L, Malavade D, Medlock M, McLeod J "Effect of gastric pH, dosing regimen and prandial state, food and meal timing relative to dose, and gastro-intestinal motility on absorption and pharmacokinetics of the antifungal posaconazole." 18th European Congress of Clinical Microbiology and Infectious Diseases April (2008): 20
- Neubauer WC, Engelhardt M, Konig A, et al. "Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method." Antimicrob Agents Chemother 54 (2010): 4029-32
- Vaes M, Hites M, Cotton F, et al. "Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplasic syndrome." Antimicrob Agents Chemother 56 (2012): 6298-303
- Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P "Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole: Monitoring of Intraluminal and Plasma Drug Concentrations." Clin Pharmacokinet 50 (2011): 725-34
- Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ "Multicenter study of posaconazole therapeutic drug monitoring: exposure-response and factors affecting concentration." Antimicrob Agents Chemother 56 (2012): 5503-10
- "Product Information. Noxafil (posaconazole)." Schering-Plough Corporation, Kenilworth, NJ.
- Krishna G, Abutarif M, Xuan F, Martinho M, Angulo D, Cornely OA "Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome." Pharmacotherapy 28 (2008): 1223-32
Generic Name: famotidine
Brand name: Heartburn Relief, Pepcid, Pepcid AC, Pepcid AC Maximum Strength, Pepcid AC Chewable Tablets, Pepcid Oral Suspension
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Noxafil-Pepcid AC Chewable Tablets
- Noxafil-Pepcid AC Maximum Strength
- Noxafil-Pepcid Complete
- Noxafil-Pepcid Oral Suspension
- Noxafil-Peptic Relief
- Noxafil-Pepto-Bismol
- Pepcid AC-Noxafil (Posaconazole Delayed-Release Tablets)
- Pepcid AC-Noxafil (Posaconazole Injection)
- Pepcid AC-Noxafil (Posaconazole Oral Suspension)
- Pepcid AC-Noxafil Intravenous
- Pepcid AC-Noxifol-D
- Pepcid AC-Noxivent